Back to Search Start Over

Donanemab-azbt (Kisunla).

Source :
Internal Medicine Alert. 8/15/2024, Vol. 46 Issue 15, p1-8. 8p.
Publication Year :
2024

Abstract

The article reports on the approval by the U.S. Food and Drug Administration on Donanemab, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, for the treatment of Alzheimer's disease, following aducanumab and lecanemab.

Details

Language :
English
ISSN :
0195315X
Volume :
46
Issue :
15
Database :
Academic Search Index
Journal :
Internal Medicine Alert
Publication Type :
Periodical
Accession number :
179361093